Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 11, 2007 Brian Orelli	Everybody Loves RNAi Roche is the latest firm to (over)pay for the hottest new drug technology. Alnylam announced that it licensed some of its intellectual property to Roche for $331 million. Investors, take note.
The Motley Fool September 10, 2007 Brian Orelli	Double Your RNA Pleasure Alnylam and ISIS join together to work on microRNAs. Their joint venture, called Regulus Therapeutics, combines their intellectual property in an effort to advance this new technology. Investors should take note.
The Motley Fool November 30, 2010 Brian Orelli	RNAi Is On Sale The novel technology looks more promising at these prices.
The Motley Fool September 20, 2007 Brian Orelli	A Pharma Divorce, and Good Riddance Merck and Alnylam call it quits. The only real question is why the two didn't end the partnership months ago. What will it mean to investors?
BusinessWeek February 26, 2007 Gene G. Marcial	CytRx Can 'Silence' Genes That Cause Disease Since October, shares of CytRx have more than doubled as investors zeroed in on its RNA interference technology that targets diabetes, obesity, and ALS.
The Motley Fool November 18, 2010 Travis Hoium	Alnylam Pharmaceuticals Shares Plunged: What You Need to Know Roche Holding AG announced it would end its partnership with Tekmira Pharmaceuticals, dragging Alnylam down in the fray. This move affects research for RNAi therapeutics, a focus for Alnylam.
The Motley Fool August 1, 2007 Brian Orelli	RNAi Gets Pumped Up Is a collaboration between RNAi expert Alnylam Pharmaceuticals and medical-device maker Medtronic something investors can endorse?
The Motley Fool November 6, 2006 Ralph Casale	Validation for a Biotechnology Firm? How Merck's bid to buy a competitor could affect Alnylam Pharmaceuticals. With the recent run-up in share price due to the Merck offer for Sirna, investors should wait for a better price before speculating on Alnylam.
The Motley Fool September 24, 2010 Brian Orelli	So Long and Thanks for All the Drug Candidates Alnylam and Novartis end their five-year partnership.
The Motley Fool August 15, 2006 Ralph Casale	Sirna Battles Genes Gone Bad Pharmaceutical start-up Sirna Therapeutics tests drugs to silence rogue genes. Investors, while drugs based on RNA interference may have the potential to become the next big thing in biotechnology, they're still a long, long way from becoming FDA-approved, marketable entities.
Bio-IT World November 2006 Kevin Davies	Merck's $1.1 Billion Bet on RNAi As if the 2006 Nobel Prize in Medicine or Physiology wasn't validation enough, Merck's acquisition of biotech firm Sirna for $1.1 billion last month offered evidence of the commercial implications of RNA interference gene-silencing technology.
Bio-IT World December 15, 2004 David A. Bumcrot	Identifying RNAi Drug Candidates Breakthroughs in understanding RNA's extensive role in essential cellular processes have opened up the potential for a whole new class of drugs based on RNAi.
The Motley Fool November 13, 2006 Jack Uldrich	Arrowhead: A Long-Term RNAi Play? Its majority stake in Calando Pharmaceuticals could pay dividends. Investors would be wise to continue to watch this company and wait until clinical trials have advanced to a more mature stage before considering an investment.
The Motley Fool January 9, 2009 Brian Orelli	Alnylam Holds Hands With a New Fella Is big pharma turning up its nose at RNAi drugs?
Bio-IT World July 15, 2003 Malorye Branca	Silence Is Golden RNA interference's scientific, therapeutic, and economic potential is unquestionable, but some sticky questions still remain.
The Motley Fool October 5, 2006 Ralph Casale	RNAi: Nobel Prize-Winning Biotechnology While drugs based on RNAi knockdown technology may have the potential to become the next big thing in biotechnology, they are still a long way from becoming FDA-approved marketable entities. But it's never too soon to start keeping an eye on the future. Investors, take note.
The Motley Fool March 24, 2008 Brian Orelli	Alnylam Authorizes Again The pharmaceutical's latest patent-licensing deal won't be immediately lucrative.
The Motley Fool February 9, 2006 Jason Mac Gurn	RNA: Rule Breaker Nucleic Acid Investors, new RNA-based technologies may be the next revolution in biopharmaceuticals. ISIS Pharmaceuticals... Sirna Therapeutics... Alnylam Pharmaceuticals...
Chemistry World June 19, 2015 Rebecca Trager	Alnylam accuses Dicerna of stealing trade secrets The US biopharmaceutical company Alnylam has filed a 'trade secret misappropriation' lawsuit against fellow Cambridge-based firm Dicerna.
Chemistry World October 2, 2006 Bea Perks	RNAi Pioneers Win Nobel Prize for Medicine Molecular biologists Andrew Fire and Craig Mello have been awarded this year's Nobel prize in physiology or medicine for their discovery of RNA interference.
Chemistry World January 25, 2010 Hayley Birch	Stabilising RNAs enhances gene silencing in tumours South Korean scientists have found a way to stabilise therapeutic RNA molecules, using chemical modifications, so that they can be more smoothly trafficked into cells.
Bio-IT World December 15, 2004 Zachary Zimmerman	Silence Is Golden Life Science Insights believes that RNAi therapeutics will dramatically affect the pharmaceutical and healthcare industries, becoming the next major class of therapeutics, joining small molecules, proteins, and monoclonal antibodies.
The Motley Fool February 28, 2011 Brian D. Pacampara	Next-Generation Drug Technologies Battle It Out Alnylam and Sangamo BioSciences have different ways to manipulate proteins to fight disease.
Bio-IT World December 15, 2004 Nancy Weil	Running Interference The revolution in RNA interference has galvanized basic research. Now, some biopharmas are pushing the technology from the laboratory to the clinic.
The Motley Fool May 18, 2007 Mike Havrilla	Ample Opportunities for Alnylam The biotech's RNAi pipeline and cutting-edge technology make it a prime takeover candidate. Investors, take note.
The Motley Fool May 28, 2008 Brian Orelli	A Partnership of Habitual Deal Makers A partnership between these two companies gives Alnylam another $150 million to pad its coffers with and Takeda a call option on an unproven but promising set of drugs.
Bio-IT World November 2005 Robert M. Frederickson	Innovations in Interference RNAi has moved from phenomenon to promising drug in less than five years, but it also has potential to be a tool used in drug discovery.
The Motley Fool February 29, 2008 Brian Orelli	RNAi Works -- Maybe Alnylam presents the first proof of concept that RNAi works in humans, but where's the proof that it cures a disease?
Chemistry World January 20, 2011 Hayley Birch	Programmable RNA promising for bio-compatible therapies Programmable nanostructures based on ribonucleic acid could be used as vessels for shipping therapeutic molecules into cells, according to US scientists.
Chemistry World July 17, 2012 Simon Perks	Synthetic nanozymes silence hepatitis C Researchers at the University of Florida, US, have discovered that an artificial nanoparticle complex, known as a nanozyme, can help to treat viral infections by 'shutting off' their genetic material.
Chemistry World April 28, 2008 Victoria Gill	Gene silencing gets fat A team of researchers in the US has developed fat-like nanoparticles that can carry fragments of RNA into cells, bring treatments based on gene silencing a step closer.
Bio-IT World November 2005 Nancy Weil	Dharmacon, Institutes Form siRNA Global Initiative The company has formed a global alliance with leading biomedical research centers aimed at speeding scientific and medical discoveries now that the first complete siRNA (small interfering RNA) library is available for targeting genes in the human genome.
Chemistry World April 20, 2009 James Urquhart	New method reveals small molecule-RNA conjugates US scientists using novel chemical screening methods have discovered a new class of small molecules connected to RNA, suggesting that cellular RNA may be more chemically diverse than previously thought.
Managed Care November 2003 Thomas Morrow	Making Sense of Antisense and Interference Treatments that interfere with protein synthesis at the cellular level will soon be debated in medical policy committee meetings.
Chemistry World March 21, 2010 Simon Hadlington	Nanoparticles successfully deliver RNA interference in cancer patients The system aims to exploit the phenomenon of RNA interference, where short sequences of double-stranded RNA, called small interfering RNA or siRNA, can trigger the disruption of the manufacture of certain proteins in a cell.
Bio-IT World December 15, 2004 William Marshall	Applications of RNAi RNA interference is a highly coordinated gene regulatory mechanism that appears to be highly conserved across all metazoans studied thus far.
Pharmaceutical Executive October 1, 2008	The other half of an HIV mystery is solved When HIV infects a human immune cell, which of the cell's own genes play a role?
Bio-IT World November 2005 G. Steven Burrill	Biotech Posts Strong Third Quarter Despite overall subpar numbers in September, as compared with the previous four months, this was another excellent quarter for biotech... A good quarter for collaborations... IPO windows open slowly... Biotech still attractive for big pharmaceuticals...
Chemistry World November 5, 2007 Lewis Brindley	Silencing the Pests Two teams of scientists have uncovered a new way to protect crops from two serious insect pests. The teams made use of a process called RNA interference to silence critical genes in the bodies of the insect larvae and stopped them growing.
Bio-IT World March 2007 Kevin Davies	Leading by Example At Cambridge Healthtech Institute's annual Pharmaceutical and Biotech Leader's Summit, drug industry executives provided accounts of the profound organizational and technological changes that are helping organizations overcome industry-wide challenges.
Bio-IT World June 2005 Nancy Weil	Dharmacon Signs Library Deal The biopharma is providing its genome-wide short-interfering RNA (siRNA) library to Millennium Pharmaceuticals. This is the first commercial siRNA collection that targets genes across the entire human genome, encompassing some 22,000 genes.
Chemistry World January 31, 2008 John Bonner	RNAi Scores Victory Against Crohn's Disease in Mice Thousands of people suffering from the debilitating gut condition Crohn's disease could experience relief from their symptoms through a technique that blocks production of a key protein in the inflammation process.
The Motley Fool January 31, 2011 Brian Orelli	Time to Buy Into Stem Cells? New developments bring this analyst a step closer to opening his wallet.
Chemistry World July 23, 2012 Melissae Fellet	RNA wrapper protects small molecules Step aside benzene rings, there's a new protecting group in town. Dutch researchers have used a strand of RNA to cover portions of a complex small molecule. They then chemically modified a portion of the molecule not covered by the RNA.
Scientific American June 2005 JR Minkel	RNA to the Rescue The spectacular discovery that a species of plant can summon up genes its parents have lost highlights biologists' increasing recognition of RNA as a more versatile and important molecule in its own right.
The Motley Fool September 8, 2006 Ralph Casale	Genta's Down, but Is It Out? An FDA advisory committee voted not to recommend Genta's lead drug, Genasense, for approval. The news has knocked Genta's stock down by nearly two-thirds over the past week.
Bio-IT World March 2006	News Blast Merck/Phase Forward... Curbing a Pandemic... Focused Trials... Collaboration...
IEEE Spectrum March 2011 Lucks & Arkin	Synthetic Biology's Hunt for the Genetic Transistor How genetic circuits will unlock the true potential of bioengineering
The Motley Fool June 9, 2009 Brian Orelli	Alnylam Lays Down a Sacrifice Bunt RNAi is still an unproven technology, and there's plenty of chances for it to strike out.
Bio-IT World December 15, 2004 Samarsky & Welch	An Unusual Path for RNAi Technology Traditionally, development of novel technologies and research tools follow the basic scientific discoveries.